If treatments such as new biologic drugs for the treatment of rheumatoid arthritis are approved for use in NHS Scotland by the Scottish Medicines Consortium (SMC), NHS boards are required to fund them from their existing allocations, and are expected to ensure that they are made available to treat clinical need.